The New Boyalife Investment Inc Holding in Cesca Therapeutics Inc
Boyalife Investment Inc filed with the SEC SC 13D/A form for Cesca Therapeutics Inc. The form can be accessed here: 000168316816000483. As reported in Boyalife Investment Inc’s form, the filler as of late owns 62.3% or 6,102,941 shares of the Health Care–company.
Cesca Therapeutics Inc stake is a new one for the and it was filed because of activity on November 3, 2016. We feel this shows Boyalife Investment Inc’s positive view for the stock.
Reasons Why Boyalife Investment Inc Bought – Cesca Therapeutics Inc Stock
Item 4. Purpose of Transaction
Item 4 is hereby supplemented with the following:
On November 3, 2016, the Reporting Person, which individuallyowns 62.3% of the outstanding shares of common stock of the Issuer, acted in accordance with the Company’s certificate ofincorporation and bylaws by written consent of the stockholders holding a majority of the shares of the Issuer to remove each ofMr. Craig W. Moore, Mr. Mark Bagnall and Mr. Robin Stracey from the board of directors of the Issuer (the “Board”)and to elect the Reporting Person’s nominee, Ms. Vivian Liu, as a new director on the Board of the Issuer. The Boardsubsequently acted to align the Company’s and the Board’s interests with those of the Issuer’s shareholders,including by executing changes to existing management of the Company (“Management”) and specifically removing Mr. Straceyas Chief Executive Officer of the Company.
The Reporting Person intends to continue to discuss such mattersidentified above not only with Management and the Board, but also with other shareholders of the Issuer and certain third partiesand may take other steps to bring about changes to increase shareholder value, including but not limited to further changes involvingBoard composition, as well as pursue other plans or proposals that relate to or would result in any of the matters set forth inclauses (a) through (j) of Item 4 of Schedule 13D.
The Reporting Person intends to reviewits investment in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer’sfinancial position and strategic direction, actions taken by the Board, price levels of the Shares, other investment opportunitiesavailable to the Reporting Person, market conditions and general economic and industry conditions, the Reporting Person may takesuch actions with respect to its investment in the Issuer as it deems appropriate, including, without limitation, purchasing additionalShares or other financial instruments related to the Issuer or selling some or all of its beneficial or economic holdings, engagingin hedging or similar transactions with respect to the securities relating to the Issuer and/or otherwise changing its intentionwith respect to any and all matters referred to in Item 4 of Schedule 13D.
Cesca Therapeutics Inc Institutional Sentiment
Latest Security and Exchange filings show 19 investors own Cesca Therapeutics Inc. The institutional ownership in Q3 2015 is low, at 102.86% of the outstanding shares. This is increased by 4424377 the total institutional shares. 10069739 were the shares owned by these institutional investors. In total 6 funds opened new Cesca Therapeutics Inc stakes, 2 increased stakes. There were 1 that closed positions and 3 reduced them.
Commerzbank Aktiengesellschaft is an institutional investor bullish on Cesca Therapeutics Inc, owning 104346 shares as of Q3 2015 for less than 0.01% of its portfolio. Whittier Trust Co owns 5000 shares or less than 0.01% of its portfolio. PA Valley National Advisers Inc have less than 0.01% of their stock portfolio for 746 shares. Further, Hanson Mcclain Inc reported stake worth less than 0.01% of its US stock portfolio. The NJ Sabby Management Llc owns 3500037 shares. Cesca Therapeutics Inc is 0.08% of the manager’s US portfolio.
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.
SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.
Cesca Therapeutics Inc (NASDAQ:KOOL) has declined 27.74% since April 4, 2016 and is downtrending. It has underperformed by 28.83% the S&P500.
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The company has a market cap of $28.00 million. The Firm develops and markets integrated cellular therapies and delivery systems. It currently has negative earnings. The Firm is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.
Cesca Therapeutics Inc (NASDAQ:KOOL) Ratings Coverage
Out of 2 analysts covering Cesca Therapeutics (NASDAQ:KOOL), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. $2 is the highest target while $1 is the lowest. The $1.50 average target is -47.00% below today’s ($2.83) stock price. Cesca Therapeutics has been the topic of 4 analyst reports since August 25, 2015 according to StockzIntelligence Inc. Maxim Group downgraded the stock to “Hold” rating in Tuesday, December 22 report. The firm has “Sell” rating by Zacks given on Tuesday, August 25. As per Monday, September 21, the company rating was upgraded by H.C. Wainwright. The stock has “Buy” rating given by Maxim Group on Tuesday, November 17.
More notable recent Cesca Therapeutics Inc (NASDAQ:KOOL) news were published by: Bizjournals.com which released: “Cesca Therapeutics shares jump on positive results from clinical study” on August 03, 2016, also Bizjournals.com with their article: “Chinese stem-cell research company takes control of Rancho Cordova’s Cesca …” published on August 26, 2016, Bizjournals.com published: “Shares of Rancho Cordova-based Cesca Therapeutics jump 27 percent in a day” on October 24, 2016. More interesting news about Cesca Therapeutics Inc (NASDAQ:KOOL) were released by: Globenewswire.com and their article: “Cesca Therapeutics Granted Two Patents for Rapid Infusion of Autologous Bone …” published on September 19, 2016 as well as Globenewswire.com‘s news article titled: “Cesca Therapeutics Provides Update on FDA Review of Investigational Device …” with publication date: August 01, 2016.
According to Zacks Investment Research, “Cesca Therapeutics Inc. is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It also develops and manufactures automated blood and bone marrow processing systems and companion disposable products that enable the separation, processing and preservation of cell and tissue therapy products. The Company sells its products in approximately 30 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. Cesca Therapeutics Inc., formerly known as ThermoGenesis Corp., is headquartered in Rancho Cordova, California.”
KOOL Company Profile
Cesca Therapeutics Inc., incorporated on July 3, 1986, is clinical-stage biotechnology company. The Firm develops and markets integrated cellular therapies and delivery systems. The Firm is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Firm focuses on the business of research, development and commercialization of autologous cell therapeutics for use in the regenerative medicine industry.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.